Thu, Dec 25, 2014, 9:38 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

locke12 6 posts  |  Last Activity: Oct 23, 2014 3:43 PM Member since: Nov 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Kovner bought 1.25 million shares at 4.01

    by jk4763 Oct 23, 2014 9:05 AM
    locke12 locke12 Oct 23, 2014 3:43 PM Flag

    you're an idiot man. Come on... I'm not going to argue that this stock couldn't trade for less, but you are wrong in you're assessment of the CEO. She's obviously no scientist and don't you think they would have hired a scientist if that's what this company needed. That's clearly why the old one is gone. What has been discovered and what will come has probably already been identified. She is going to rebuild this company and make it extremely profitable. If I had to guess, Bachall is still going to become very wealthy from what she is going to do and what he couldn't do... This is going to be one of those end of the day pops to 10, then trade for a month in that 10-12 range then pop to 17. Once they have an approved drug, she is going to do what she was hired to do; build a team and get this rock shining. This stock will trade around 37-42 in 2017. You have no idea. Listen to the calls and think about what they're working on.

    Sentiment: Strong Buy

  • Reply to

    CEO

    by jcal4uhealth Oct 13, 2014 4:12 PM
    locke12 locke12 Oct 16, 2014 1:07 PM Flag

    hey man, just don't say I didn't give a heads up.

  • Reply to

    CEO

    by jcal4uhealth Oct 13, 2014 4:12 PM
    locke12 locke12 Oct 15, 2014 2:50 PM Flag

    I'd be a fool not to re-enter at this price, even a small position... I didn't lose everything and this will rebound... Per my $7 prediciton, the only assumption that I can rationalize is that based on last November after it tanked to 3.75, I assumed that it had to rebound because the data although not great at the time, wasn't bad enough. Within a few months and unexpected announcements it climbed to 7. I think the same thing happens here; large insider purchases again, no report of "poor" data, new CEO. It lends itself to a speculative strong buy and investors are going to want in well in advance of mid-2015.

  • Reply to

    CEO

    by jcal4uhealth Oct 13, 2014 4:12 PM
    locke12 locke12 Oct 15, 2014 12:06 PM Flag

    Ganetispib, HsP90, the secret hot chocolate formula... What do you mean, what data. What have they been working lately?? When the Gannet randomized trials in Europe were announced, the stock surged. No one knew about it. SPY trials in San Antonio, no one knew, stock moved. I understand it wasn't ground breaking info, it's still encouraging. Everyone on this board seems to think the obvious is going to materialize into something expected. This stock hasn't moved on anything expected, except on the bad news... So, the data, that we know nothing about, is the catalyst... I can tell you with certainty that there is nothing the new CEO can or will say that will cause investors to come flocking back to this stock. Gullust made it clear on the last cal that they aren't interested in being an incubator, they want to be a full service company. Whittaker's job is to build an effective team in preparation for FDA approval in 2016. Data releases and feedback from these various relationships will run us back to $7 in a couple months.

    Sentiment: Strong Buy

  • Reply to

    CEO

    by jcal4uhealth Oct 13, 2014 4:12 PM
    locke12 locke12 Oct 14, 2014 2:52 PM Flag

    What strikes me as odd, is the market sentiment. I've read many people on here claim certainty that when a new CEO was announced this was going to go back to 5, 6 or 7.. In my opinion, there's only 2 possible scenerios (given her silence) 1.the data is in fact not great and in order to prevent this from becoming a penny stock the bod struck a deal to save time and face. 2. the data isn't bad, but her job was to overhaul the team and she feels her priority is to the company and it's people, not so much the shareholders. bod said don't worry abou the stock, we'll take care of that, you just get this company running effeciently, product to market, however that may be.... Now, let's discuss stragedy for a second. There is a growing trend that women leaders are getting the job done more effectively. I don't think that choosing her was a total merit based decision, although it very much was also. Her profile on it's own will generate interest. This was a rebranding effort. The bod, on paper, are not dumb people. Wall Street right now is testing her poise and confidence as an actual CEO. From what I've read about Kovner, his purchase of those 300,000 shares was an anty for the poker game that's about to begin. The market is not impressed with anything that isn't right now. Any day, most likely after the bell, some kind of positive relationship or data will be realeased and the hedge funds are going to want to raise the stakes.... Short interest has been declining, it's a wait and see game right now.

    Sentiment: Strong Buy

  • locke12 by locke12 Oct 9, 2014 5:25 PM Flag

    Look at the 2 year chart of Arrowhead Research. I like to think that Synta is very much going to have a similar one.

    Sentiment: Strong Buy

SNTA
2.63+0.02(+0.77%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST